Oppenheimer reaffirmed their buy rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research note issued to investors on Monday. Oppenheimer currently has a $83.00 target price on the biopharmaceutical company’s stock.

AGIO has been the subject of a number of other reports. Cann reissued a buy rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Credit Suisse Group lifted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research report on Thursday, November 2nd. ValuEngine raised Agios Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, September 1st. SunTrust Banks reaffirmed a buy rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Royal Bank of Canada started coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating and a $78.00 target price for the company. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $75.70.

Shares of Agios Pharmaceuticals (AGIO) opened at $61.42 on Monday. Agios Pharmaceuticals has a 1 year low of $39.24 and a 1 year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.63) EPS. equities analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $65.47, for a total value of $65,470.00. Following the transaction, the director now directly owns 86,394 shares in the company, valued at approximately $5,656,215.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $67.23, for a total value of $144,275.58. The disclosure for this sale can be found here. Insiders sold a total of 167,746 shares of company stock worth $11,410,226 over the last quarter. Company insiders own 5.43% of the company’s stock.

A number of hedge funds have recently made changes to their positions in AGIO. FMR LLC grew its stake in Agios Pharmaceuticals by 14.1% during the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after buying an additional 895,584 shares during the last quarter. Vanguard Group Inc. grew its stake in Agios Pharmaceuticals by 23.8% during the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after buying an additional 617,379 shares during the last quarter. BlackRock Inc. grew its stake in Agios Pharmaceuticals by 23.5% during the 2nd quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after buying an additional 508,306 shares during the last quarter. Alkeon Capital Management LLC purchased a new position in Agios Pharmaceuticals during the 3rd quarter worth $30,489,000. Finally, Janus Henderson Group PLC purchased a new position in Agios Pharmaceuticals during the 2nd quarter worth $20,423,000. Hedge funds and other institutional investors own 94.38% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/12/agios-pharmaceuticals-agio-receives-buy-rating-from-oppenheimer.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.